FeesSafety
Pluang+

Optimi Health advances Phase 2b psilocybin and Phase 3 MDMA trials for depression and PTSD in 2027

Company Fundamentals
18 Nov 2026, 14:30 WIB
GlobeNewsWire
View Source
Bullish
Optimi Health advances Phase 2b psilocybin and Phase 3 MDMA trials for depression and PTSD in 2027

Optimi Health announced plans for 2027 to advance its clinical trials for mental health treatments, including a Phase 2b randomized, double-blind trial of naturally derived psilocybin (OPTI-101) for severe major depressive disorder, with dosing starting in Q1 2027 and topline data expected in 2028. The company also plans a Health Canada-cleared Phase 3 trial of MDMA-assisted therapy (OPTI-201) for PTSD in veterans and front-line workers, starting in 2027, alongside preparing U.S. FDA IND filings for both drugs. Additionally, Optimi is set to produce ibogaine capsules for research and has agreed to a shares-for-debt settlement with its CEO. These developments position Optimi to potentially expand its psychedelic drug offerings in Canada, Australia, and the U.S., pending regulatory approvals.

Optimi Health's 2027 clinical trial plans provide context for readers interested in health sector developments. For readers following health-sector US stocks on Pluang, here is the market snapshot as of Nov 18, 2026 19:21 WIB: out of 150 priced stocks, 55 rose and 86 fell. Notable movers include FLNA at USD 0.47 with a 1-day change of -2.22% and Pluang order activity of 97% Sell / 3% Buy, TNGX at USD 22.60 with a 1-day change of +2.22%, and CTXR at USD 0.53 with a 1-day change of +2.16% and Pluang order activity of 90% Sell / 10% Buy. The most notable figure is FLNA's 97% sell order activity.

More News

Lowe's beats Q3 earnings estimates and raises full-year sales outlook.

Lowe's beats Q3 earnings estimates and raises full-year sales outlook.

Lowe's reported adjusted earnings per share of $3.10, surpassing estimates of $2.88, and revenue of $22.80 billion, beating the $22.40 billion forecast. Comparable sales rose 1.8%, driven by strong online and professional services sales. The company ...

Company Fundamentals
Bullish
50 minutes ago
Major Memphis health system expands Daxor's blood volume testing to new outpatient site with 24-hour results.

Major Memphis health system expands Daxor's blood volume testing to new outpatient site with 24-hour results.

Daxor Corporation announced that a major Memphis health system has expanded its Blood Volume Analysis (BVA) program to an additional hospital outpatient site using Daxor’s ezBVA Lab service. This expansion allows the outpatient clinic to receive bloo...

Market News
Bullish
54 minutes ago
Microsoft shares drop 2.27% after global outages despite Oppenheimer's Outperform rating

Microsoft shares drop 2.27% after global outages despite Oppenheimer's Outperform rating

Microsoft's stock fell 2.27% to $506.24 following global outages affecting its Copilot, Teams, and Outlook services. The outages, attributed to server issues rather than cyberattacks, raised concerns amid broader software sector weakness. Oppenheimer...

Market News
Bearish
1 hour ago
Target posts strongest sales growth in 5 years, raises annual sales growth target to 6%.

Target posts strongest sales growth in 5 years, raises annual sales growth target to 6%.

Target Corporation reported earnings per share of $2.65, beating estimates of $2.08, and revenue of $27.1 billion, surpassing the $26.5 billion forecast. The company achieved its strongest quarterly sales growth in about five years, with net sales up...

Company Fundamentals
Bullish
1 hour ago
Aquestive Therapeutics to present at Piper Sandler Healthcare Conference on Dec 2, 2026

Aquestive Therapeutics to present at Piper Sandler Healthcare Conference on Dec 2, 2026

Aquestive Therapeutics announced its participation in the Piper Sandler 38th Annual Healthcare Conference from December 1-3, 2026, in New York City. CEO Daniel Barber will present on December 2 at 10:30 am ET, with one-on-one investor meetings schedu...

Market News
Neutral
1 hour ago
banner-footerbanner-footer

Invest & Trade with
#1 Award-Winning Investment Super App